ASSERTIO HOLDINGS INC (ASRT) Fundamental Analysis & Valuation

NASDAQ:ASRT • US04546C3043

Current stock price

13.37 USD
-0.35 (-2.55%)
At close:
13.372 USD
+0 (+0.01%)
After Hours:

This ASRT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. ASRT Profitability Analysis

1.1 Basic Checks

  • ASRT had negative earnings in the past year.
  • ASRT had a positive operating cash flow in the past year.
  • In the past 5 years ASRT reported 4 times negative net income.
  • Of the past 5 years ASRT 4 years had a positive operating cash flow.
ASRT Yearly Net Income VS EBIT VS OCF VS FCFASRT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

1.2 Ratios

  • ASRT has a Return On Assets of -8.90%. This is in the better half of the industry: ASRT outperforms 68.75% of its industry peers.
  • ASRT has a better Return On Equity (-26.89%) than 64.06% of its industry peers.
Industry RankSector Rank
ROA -8.9%
ROE -26.89%
ROIC N/A
ROA(3y)-32.33%
ROA(5y)-21.33%
ROE(3y)-69.93%
ROE(5y)-52.34%
ROIC(3y)N/A
ROIC(5y)N/A
ASRT Yearly ROA, ROE, ROICASRT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

  • ASRT has a Gross Margin of 68.16%. This is in the better half of the industry: ASRT outperforms 77.60% of its industry peers.
  • ASRT's Gross Margin has declined in the last couple of years.
  • ASRT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.36%
GM growth 5Y-6.47%
ASRT Yearly Profit, Operating, Gross MarginsASRT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. ASRT Health Analysis

2.1 Basic Checks

  • ASRT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ASRT has been increased compared to 1 year ago.
  • The number of shares outstanding for ASRT has been increased compared to 5 years ago.
  • Compared to 1 year ago, ASRT has a worse debt to assets ratio.
ASRT Yearly Shares OutstandingASRT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
ASRT Yearly Total Debt VS Total AssetsASRT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • Based on the Altman-Z score of -2.16, we must say that ASRT is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -2.16, ASRT is in line with its industry, outperforming 44.79% of the companies in the same industry.
  • ASRT has a debt to FCF ratio of 3.06. This is a good value and a sign of high solvency as ASRT would need 3.06 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 3.06, ASRT belongs to the top of the industry, outperforming 90.63% of the companies in the same industry.
  • A Debt/Equity ratio of 0.37 indicates that ASRT is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.37, ASRT is in line with its industry, outperforming 40.63% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF 3.06
Altman-Z -2.16
ROIC/WACCN/A
WACC9.38%
ASRT Yearly LT Debt VS Equity VS FCFASRT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 1.58 indicates that ASRT should not have too much problems paying its short term obligations.
  • ASRT's Current ratio of 1.58 is on the low side compared to the rest of the industry. ASRT is outperformed by 68.23% of its industry peers.
  • ASRT has a Quick Ratio of 1.43. This is a normal value and indicates that ASRT is financially healthy and should not expect problems in meeting its short term obligations.
  • ASRT has a Quick ratio of 1.43. This is in the lower half of the industry: ASRT underperforms 64.58% of its industry peers.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 1.43
ASRT Yearly Current Assets VS Current LiabilitesASRT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. ASRT Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 72.60% over the past year.
  • The Revenue has grown by 9.21% in the past year. This is quite good.
  • The Revenue for ASRT have been decreasing by -11.45% on average. This is quite bad
EPS 1Y (TTM)72.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%500%
Revenue 1Y (TTM)9.21%
Revenue growth 3Y4.03%
Revenue growth 5Y-11.45%
Sales Q2Q%69.36%

3.2 Future

  • Based on estimates for the next years, ASRT will show a very strong growth in Earnings Per Share. The EPS will grow by 33.07% on average per year.
  • Based on estimates for the next years, ASRT will show a small growth in Revenue. The Revenue will grow by 3.55% on average per year.
EPS Next Y-90.1%
EPS Next 2Y7.27%
EPS Next 3Y30.49%
EPS Next 5Y33.07%
Revenue Next Year-9.11%
Revenue Next 2Y-2.76%
Revenue Next 3Y3.38%
Revenue Next 5Y3.55%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ASRT Yearly Revenue VS EstimatesASRT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M
ASRT Yearly EPS VS EstimatesASRT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 20 -20 40 -40 60

More info and screens

Find the best growth stocksShow best growing peers

2

4. ASRT Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ASRT. In the last year negative earnings were reported.
  • Also next year ASRT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ASRT Price Earnings VS Forward Price EarningsASRT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, ASRT is valued cheaper than 94.79% of the companies in the same industry.
Industry RankSector Rank
P/FCF 6.71
EV/EBITDA -1.43
ASRT Per share dataASRT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ASRT's earnings are expected to grow with 30.49% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.27%
EPS Next 3Y30.49%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ASRT Dividend Analysis

5.1 Amount

  • No dividends for ASRT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ASRT Fundamentals: All Metrics, Ratios and Statistics

ASSERTIO HOLDINGS INC

NASDAQ:ASRT (3/20/2026, 8:00:01 PM)

After market: 13.372 +0 (+0.01%)

13.37

-0.35 (-2.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-10
Earnings (Next)05-11
Inst Owners33.4%
Inst Owner Change-93.6%
Ins Owners1.25%
Ins Owner Change-0.01%
Market Cap85.84M
Revenue(TTM)137.35M
Net Income(TTM)-28.45M
Analysts82
Price Target38.19 (185.64%)
Short Float %4.07%
Short Ratio5.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)59.56%
Min EPS beat(2)-119.3%
Max EPS beat(2)238.41%
EPS beat(4)2
Avg EPS beat(4)2.16%
Min EPS beat(4)-145.1%
Max EPS beat(4)238.41%
EPS beat(8)3
Avg EPS beat(8)-366.43%
EPS beat(12)4
Avg EPS beat(12)-302.51%
EPS beat(16)7
Avg EPS beat(16)-212.97%
Revenue beat(2)2
Avg Revenue beat(2)41.15%
Min Revenue beat(2)2.84%
Max Revenue beat(2)79.46%
Revenue beat(4)3
Avg Revenue beat(4)21.67%
Min Revenue beat(4)-5.64%
Max Revenue beat(4)79.46%
Revenue beat(8)5
Avg Revenue beat(8)11.34%
Revenue beat(12)8
Avg Revenue beat(12)6.31%
Revenue beat(16)12
Avg Revenue beat(16)6.58%
PT rev (1m)0%
PT rev (3m)1306.1%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1405.56%
EPS NY rev (1m)0%
EPS NY rev (3m)-1421.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.62
P/FCF 6.71
P/OCF 6.71
P/B 0.81
P/tB 1.68
EV/EBITDA -1.43
EPS(TTM)-3
EYN/A
EPS(NY)-2.93
Fwd EYN/A
FCF(TTM)1.99
FCFY14.9%
OCF(TTM)1.99
OCFY14.9%
SpS21.39
BVpS16.48
TBVpS7.96
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.9%
ROE -26.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.16%
FCFM 9.31%
ROA(3y)-32.33%
ROA(5y)-21.33%
ROE(3y)-69.93%
ROE(5y)-52.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.36%
GM growth 5Y-6.47%
F-Score4
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF 3.06
Debt/EBITDA 2.65
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion 86.6%
Profit Quality N/A
Current Ratio 1.58
Quick Ratio 1.43
Altman-Z -2.16
F-Score4
WACC9.38%
ROIC/WACCN/A
Cap/Depr(3y)16.81%
Cap/Depr(5y)10.15%
Cap/Sales(3y)3.56%
Cap/Sales(5y)2.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%500%
EPS Next Y-90.1%
EPS Next 2Y7.27%
EPS Next 3Y30.49%
EPS Next 5Y33.07%
Revenue 1Y (TTM)9.21%
Revenue growth 3Y4.03%
Revenue growth 5Y-11.45%
Sales Q2Q%69.36%
Revenue Next Year-9.11%
Revenue Next 2Y-2.76%
Revenue Next 3Y3.38%
Revenue Next 5Y3.55%
EBIT growth 1Y0.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year202.8%
EBIT Next 3Y60.57%
EBIT Next 5Y42.08%
FCF growth 1Y-76.41%
FCF growth 3Y69.74%
FCF growth 5Y-21.57%
OCF growth 1Y-81.89%
OCF growth 3Y68.7%
OCF growth 5Y-21.83%

ASSERTIO HOLDINGS INC / ASRT Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ASSERTIO HOLDINGS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ASRT.


What is the valuation status of ASSERTIO HOLDINGS INC (ASRT) stock?

ChartMill assigns a valuation rating of 2 / 10 to ASSERTIO HOLDINGS INC (ASRT). This can be considered as Overvalued.


What is the profitability of ASRT stock?

ASSERTIO HOLDINGS INC (ASRT) has a profitability rating of 2 / 10.


What is the earnings growth outlook for ASSERTIO HOLDINGS INC?

The Earnings per Share (EPS) of ASSERTIO HOLDINGS INC (ASRT) is expected to decline by -90.1% in the next year.